Characteristics of L-PRP preparations for treating Achilles tendon rupture within the PATH-2 study

Platelets. 2021 Feb 17;32(2):273-279. doi: 10.1080/09537104.2020.1849604. Epub 2020 Nov 26.

Abstract

Platelet-rich plasma (PRP) is an autologous preparation that has been claimed to improve healing and mechanobiological properties of tendons both in vitro and in vivo. In this sub-study from the PATH-2 (PRP in Achilles Tendon Healing-2) trial, we report the cellular and growth factor content and quality of the Leukocyte-rich PRP (L-PRP) (N = 103) prepared using a standardized commercial preparation method across 19 different UK centers. Baseline whole blood cell counts (red cells, leukocyte and platelets) demonstrated that the two groups were well-matched. L-PRP analysis gave a mean platelet count of 852.6 x 109/L (SD 438.96), a mean leukocyte cell count of 15.13 x 109/L (SD 10.28) and a mean red blood cell count of 0.91 x 1012/L (SD 1.49). The activation status of the L-PRP gave either low or high expression levels of the degranulation marker CD62p before and after ex-vivo platelet activation respectively. TGF-β, VEGF, PDGF, IGF and FGFb mean concentrations were 131.92 ng/ml, 0.98 ng/ml, 55.34 ng/ml, 78.2 ng/ml and 111.0 pg/ml respectively with expected correlations with both platelet and leukocyte counts. While PATH-2 results demonstrated that there was no evidence L-PRP is effective for improving clinical outcomes at 24 weeks after Achilles tendon rupture, our findings support that the majority of L-PRP properties were within the method specification and performance.

Keywords: Achilles; platelet-rich plasma; rupture; tendon.

Publication types

  • Multicenter Study

MeSH terms

  • Achilles Tendon / drug effects*
  • Achilles Tendon / physiopathology
  • Female
  • Humans
  • Male
  • Platelet-Rich Plasma / metabolism*
  • Wound Healing / drug effects*